By vgreene, 30 October, 2020 KEY FINDINGS early TCZ use assoc w lower in hospital mortality in critically ill
By vgreene, 30 October, 2020 Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID 19
By vgreene, 30 October, 2020 No statistical difference in clinical worsening w in 14 days TCZ 28 3 vs SOC 27 RR 1 05 95 CI 0 59 1 86
By vgreene, 30 October, 2020 Prospective open label randomized study 126 hospitalized pts median age 60y w COVID 19 pneumonia received TCZ 8 mg kg max 800 mg w in 8h of randomization w 2nd dose 12h later n 60 or SOC only n 66
By vgreene, 30 October, 2020 Study considerations randomized but open label small sample size study interrupted due to low enrollment excluded pts at risk for ICU admission significant imbalances btwn groups incl antiviral use and baseline labs
By vgreene, 30 October, 2020 Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID 19 Pneumonia A Randomized Clinical Trial
By vgreene, 30 October, 2020 No significant difference in death or vent needs on day 4 cumulative incidence of ventilation or death TCZ 24 vs usual care 36 HR 0 58 90 CI 0 33 1 no significant difference in mortality over 28 days between groups
